APAC Biosimilar Market, Forecast 2025

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

RELEASE DATE
10-Jan-2018
REGION
Asia Pacific
Research Code: P9A3-01-00-00-00
SKU: LS00279-AP-MT_21441
AvailableYesPDF Download
$4,950.00
In stock
SKU
LS00279-AP-MT_21441
$4,950.00
DownloadLink
ENQUIRE NOW

Description

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, offer an attractive opportunity for drug development and commercialization. Moreover, these are generics-driven markets, providing a positive opportunity for biosimilars development and commercialization.


Research Highlights

The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation. In the next 4–5 years, two-thirds of the patent expiries would be in biosimilars and specialty segments such as bio-betters that have high profit margins.
High revenue-churning blockbuster drugs are set to lose their patent protection in APAC during the forecast period and biosimilars companies are proactive in filing applications for marketing rights. In the pharmaceuticals market, there is a shift towards higher-value biological therapies, biosimilars, and specialty segments, where there is less competition despite high profit margins. With several biological drugs expected to lose patents by 2020, this segment is expected to experience an annual growth rate of more than 30.0% by 2020. Many Asian companies have biosimilars molecules under development, such as LG Life Sciences, Samsung Bioepis, and Celtrion. Cipla has already launched the biosimilar version in India in 2013, followed by Intas Pharmaceuticals in March 2015. Samsung Bioepis has also received approval for its biosimilar in South Korea in September 2015 for entracept.

Key Features

The key objective of this research service is to help clients identify the major growth opportunities for biosimilars across therapeutic areas such as rheumatoid arthritis, cancer, and diabetes, and understand the key challenges in the space.


Key Issues Addressed

  • What is the current scenario of the biosimilars market in APAC, and how far will it grow?
  • What are the key factors driving the market, and what are the barriers that need to be resolved?
  • Which are the key market segments to look out for, and what are the key trends and regulatory aspects?
  • Who are the key market participants involved, and where do they stand?
  • What are the factors affecting the biosimilars market in the different regions of APAC, and how will these factors affect the market?
  • What is the future of the biosimilars market in Asia?

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Purpose of the Experiential Study

5 Step Process to Transformational Growth

Scope and Segmentation

Key Questions This Study Will Answer

Key Findings

Biosimilars—Gateway to Success

Trends in Evolving Biopharmaceuticals Market

Biosimilars Ecosystem—Industry Convergence Map

Ecosystem Partnerships

Disruptive Trends in the Changing Market Landscape

Key Regions

Six Big Market Themes for Global Biosimilars Market

Market Overview

Key Challenges in the Biosimilars Market

Biosimilars Market—Timeline

Market Segmentation by Therapeutic Areas

Trends in Global Biosimilars Market

Global Biosimilar Patenting Trends

Areas Impacting Biosimilars Adoption

Attributes Impeding Physician Adoption of Biosimilars

Drivers and Restraints

Impact Mapping of Drivers and Restraints

Market Snapshot—Biosimilars Market

Percent Revenue Forecast by Region

Revenue Forecast

Revenue Forecast by Molecule Type

Revenue Forecast Discussion

Major Growth Opportunities

Growth Opportunity 1—mAb Biosimilars for Cancer

Growth Opportunity 2—Insulin Glargine Biosimilars for Diabetes

Growth Opportunity 3—mAb Biosimilars for Rheumatoid Arthritis

Strategic Imperatives for Success and Growth

Trastuzumab Biosimilars—Key Participants

Trastuzumab Biosimilars—Revenue Forecast

Trastuzumab Biosimilars—Adoption Rate and Patient Population

Trastuzumab Biosimilars—Price and Discounts

Bevacizumab Biosimilar—Key Participants

Bevacizumab Biosimilar—Revenue Forecast

Bevacizumab Biosimilar—Adoption Rate and Patient Population

Bevacizumab Biosimilar—Price and Discounts

Insulin Glargine Biosimilar—Key Participants

Insulin Glargine Biosimilar—Revenue Forecast

Insulin Glargine Biosimilar—Adoption Rate and Patient Population

Insulin Glargine Biosimilar—Price and Discounts

Etanercept Biosimilar—Key Participants

Etanercept Biosimilar—Revenue Forecast

Etanercept Biosimilar—Adoption Rate and Patient Population

Etanercept Biosimilar—Price and Discounts

Infliximab Biosimilar—Key Participants

Infliximab Biosimilar—Revenue Forecast

Infliximab Biosimilar—Adoption Rate and Patient Population

Infliximab Biosimilar—Price and Discounts

Pipeline for Adalimumab Biosimilar—Key Participants

Adalimumab Biosimilar—Revenue Forecast

Adalimumab Biosimilar—Adoption Rate and Patient Population

Adalimumab Biosimilar—Price and Discounts

APAC—A Lucrative Market for Biosimilars

APAC—Regulatory Authorities

APAC Biosimilars—Game-changing Companies

Patent Expiry for Blockbuster Bio-pharmaceuticals

APAC—Future of Biosimilars

APAC—Market Analysis

Transformation of Industry Ecosystem

Key Factors for New Entrants

Interchangeability

Interchangeability (continued)

Regional Hot Spots

Country Attractiveness

Key Companies to Watch

Mergers, Acquisitions, and Partnerships Assessment

Mergers, Acquisitions, and Partnerships Assessment (continued)

Strategies for Foreign Participants in APAC

Factors Influencing Uptake of Biosimilars in APAC

Factors Influencing Uptake of Biosimilars in APAC—Discussion

Physicians, Patients, and Pharmacists—Perceptions and Concerns

Revenue Forecast

Revenue Forecast Discussion

Market Analysis

Snapshot of Market Participants

Regulatory Environment

Strategic Imperatives for China—Key Trends

Revenue Forecast

Revenue Forecast Discussion

Snapshot of Market Participants

Regulatory Environment

Strategic Imperatives for India—Key Trends

Growth Potential of Key Segments in Bio-tech in India

Revenue Forecast

Revenue Forecast Discussion

Revenue Forecast Discussion (continued)

Snapshot of Market Participants

Regulatory Environment

Regulatory Environment (continued)

Strategic Imperatives for South Korea—Key Trends

Revenue Forecast

Revenue Forecast Discussion

Snapshot of Market Participants

Regulatory Environment

Regulatory Environment (continued)

Strategic Imperatives for Japan—Key Trends

Revenue Forecast

Revenue Forecast Discussion

Snapshot of Market Participants

Regulatory Environment

Strategic Imperatives for Australia—Key Trends

Visioning Scenarios for the Biosimilars Market

Visioning Scenarios for the Biosimilars Market (continued)

Visioning Scenarios for the Biosimilar Market (continued)

Visioning Scenarios for the Biosimilars Market (continued)

Business Model Essentials

5 Competitive Keys for Success

Future of Biosimilars in APAC

Legal Disclaimer

List of Exhibits

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

Global Regulatory Landscape

Global Regulatory Landscape Discussion

Regulations and their Impact on the Biosimilars Market

Biosimilars are Not Generics—A Comparison Between Generics, Biologics, and Biosimilars

Biosimilars are Not Generics—A Comparison Between Generics, Biologics, and Biosimilars (continued)

Biosimilars are Not Generics—A Comparison Between Generics, Biologics, and Biosimilars (continued)

Biologics and Biosimilars—Manufacturing Processes

Development Process and Technical Requirements for BiosimilarsProduction process and technical needs are complex.

Timeline for Development of a Biosimilar Medicine

Value Chain Analysis—Development of a Biosimilar

Big Pharma Companies (Innovators) Vs Biotech Firms Vs Generic Manufacturers

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, offer an attractive opportunity for drug development and commercialization. Moreover, these are generics-driven markets, providing a positive opportunity for biosimilars development and commercialization.--BEGIN PROMO--

Research Highlights

The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation. In the next 4–5 years, two-thirds of the patent expiries would be in biosimilars and specialty segments such as bio-betters that have high profit margins.
High revenue-churning blockbuster drugs are set to lose their patent protection in APAC during the forecast period and biosimilars companies are proactive in filing applications for marketing rights. In the pharmaceuticals market, there is a shift towards higher-value biological therapies, biosimilars, and specialty segments, where there is less competition despite high profit margins. With several biological drugs expected to lose patents by 2020, this segment is expected to experience an annual growth rate of more than 30.0% by 2020. Many Asian companies have biosimilars molecules under development, such as LG Life Sciences, Samsung Bioepis, and Celtrion. Cipla has already launched the biosimilar version in India in 2013, followed by Intas Pharmaceuticals in March 2015. Samsung Bioepis has also received approval for its biosimilar in South Korea in September 2015 for entracept.

Key Features

The key objective of this research service is to help clients identify the major growth opportunities for biosimilars across therapeuti

More Information
No Index No
Podcast No
Lightbox Content World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019
Author Sanjeev Kumar
WIP Number P9A3-01-00-00-00
Is Prebook No